Disease · MONDO_0005861
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Delamanid + OBR vs Placebo + OBR: Number of Participants Who Developed Resistance To Delamanid | 3 of 341 | 0 of 170 | 511 | NCT01424670 | Trial comparisons |
| Delamanid + OBR vs Placebo + OBR: deaths from any cause | 18 of 341 | 8 of 170 | 511 | NCT01424670 | Trial comparisons |
| Delamanid + OBR vs Placebo + OBR: serious adverse events | 89 of 341 | 47 of 170 | 511 | NCT01424670 | Trial comparisons |
| Experimental Arm vs Control Arm: Proportion of Death Between the Control and Investigational Arms | 5 of 79 | 2 of 89 | 168 | NCT02619994 | Trial comparisons |
| Experimental Arm vs Control Arm: deaths from any cause | 5 of 79 | 2 of 89 | 168 | NCT02619994 | Trial comparisons |
| Experimental Arm vs Control Arm: serious adverse events | 20 of 79 | 19 of 89 | 168 | NCT02619994 | Trial comparisons |
| Experimental Arm vs Control Arm: Treatment Success at the End of Treatment | 61 of 78 | 64 of 89 | 167 | NCT02619994 | Trial comparisons |
| Experimental Arm vs Control Arm: Proportion of Reverting to Positive Sputum Culture After the End of Treatment | 1 of 72 | 0 of 85 | 157 | NCT02619994 | Trial comparisons |
| Experimental Arm vs Control Arm: Treatment Success Rate | 54 of 72 | 60 of 85 | 157 | NCT02619994 | Trial comparisons |
| Experimental Arm vs Control Arm: Sputum Culture Conversion Proportion | 39 of 49 | 45 of 52 | 101 | NCT02619994 | Trial comparisons |
| Experimental Arm vs Control Arm: Sputum Culture Conversion Proportion | 35 of 49 | 42 of 52 | 101 | NCT02619994 | Trial comparisons |
| Experimental Arm vs Control Arm: Treatment Success According to Pyrazinamide Resistance (2) | 32 of 42 | 41 of 52 | 94 | NCT02619994 | Trial comparisons |
| Experimental Arm vs Control Arm: Treatment Success According to Pyrazinamide Resistance (1) | 19 of 25 | 13 of 21 | 46 | NCT02619994 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005861/comparisons